The Drugs.com Monthly Update Podcast

This September 2026 Drugs.com Monthly Update covers several new FDA approvals that provide novel treatment options and expand therapeutic possibilities.

• Zanvastro (zilganersen): A GFAP-directed antisense oligonucleotide for the treatment of Alexander disease in pediatric and adult patients. 
• Juvmo (tavapadon): A selective D1/D5 receptor partial agonist for the treatment of Parkinson's disease. 
• Isembyld (apitegromab-mstn): A myostatin-targeted treatment for children and adults with spinal muscular atrophy receiving SMN2-targeted therapy. 
• Onswik (insulin efsitora alfa-gobe): A once-weekly basal insulin for adults with type 2 diabetes mellitus. 
• Etcamah (camizestrant): An oral SERD combined with a CDK4/6 inhibitor for advanced HR-positive, HER2-negative breast cancer with an ESR1 mutation.
• Emcitate (tiratricol): A thyroid hormone receptor agonist for the treatment of peripheral thyrotoxicosis in patients with MCT8 deficiency.
• Omcazio (cabozantinib): A laurylsulfate salt capsule formulation of cabozantinib approved for advanced renal cell carcinoma, hepatocellular carcinoma, and neuroendocrine tumors, featuring administration without regard to food.
• Atebrioz (zilurgisertib): An ALK2 inhibitor for reducing new heterotopic ossification in patients aged 12 years and older with fibrodysplasia ossificans progressiva.

Chapters:

• (00:18) - Intro

• X, Facebook, YouTube
• Sign up to our newsletters
• Download the app

In our August 2026 episode of Drugs.com Monthly Update, we review the latest round of FDA approvals bringing new therapeutic strategies to patients and prescribers.

• mFLUSIVA (influenza vaccine, mRNA): A new mRNA-based seasonal flu vaccine approved for the prevention of influenza disease in adults 50 years of age and older.
• Orzeyful (oveporexton): An innovative orexin receptor 2 agonist approved for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adult patients.
• Genglycos (pariglasgene brecaparvovec-opnr): A novel gene therapy for adults and pediatric patients 8 years and older with glycogen storage disease type Ia to reduce daily cornstarch intake.
• Rasonque (daraxonrasib): A broad RAS-targeted medicine approved for previously treated adults with metastatic pancreatic adenocarcinoma.
• Bixlenvo (bictegravir and lenacapavir): A once-daily combination antiretroviral tablet for virologically suppressed adults with HIV-1 replacing their current regimen.

Chapters:

• (00:19) - Intro

• X, Facebook, YouTube
• Sign up to our newsletters
• Download the app

This July 2026 Drugs.com Monthly Update covers several new FDA approvals that provide novel treatment options and expand therapeutic possibilities.

• Gwyn Lo (ethinyl estradiol and norelgestromin): A new once-weekly transdermal patch providing low-dose estrogen and progestin for pregnancy prevention.
• Lytenava (bevacizumab-vikg): The first FDA-approved ophthalmic formulation of bevacizumab for patients with wet age-related macular degeneration.
• Simtriyo (centanafadine): A novel triple reuptake inhibitor approved for the treatment of ADHD in adults and pediatric patients 6 years and older.
• Jideytro (zidesamtinib): A brain-penetrant ROS1 inhibitor approved for adults with advanced ROS1-positive non-small cell lung cancer previously treated with a ROS1 inhibitor.
• Lipfendra (enlicitide): The first oral PCSK9 inhibitor approved to significantly reduce LDL-C in adults with hypercholesterolemia and heterozygous familial hypercholesterolemia
• Tylenol with naproxen: The first OTC combination of acetaminophen and naproxen.

Chapters:

• (00:20) - Intro

• X, Facebook, YouTube
• Sign up to our newsletters
• Download the app

This month, we're exploring advances across multiple therapeutic areas. We cover Lumvoa for thyroid eye disease, Utebzi for complicated urinary tract infections, and Tregzi for blood cancers.

• Lumvoa (veligrotug-vvze): Approved for thyroid eye disease, Lumvoa is an IGF-1R inhibitor that offers significant improvements in TED symptoms, with notable early effectiveness.
• Utebzi (tebipenem pivoxil): The first oral carbapenem approved in the U.S., providing a new option for treating complicated urinary tract infections, demonstrating efficacy comparable to intravenous options.
• Tregzi (Orca-T or allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq): A precision-engineered cell therapy for use in donor stem cell transplantation, to help rebuild the blood and immune system, and to improve chronic graft-versus-host disease (GVHD)-free survival, in adults with blood cancers (hematological malignancies).

Chapters:

• (00:21) - Intro

• X, Facebook, YouTube
• Sign up to our newsletters
• Download the app

In this May 2026 Monthly Update edition, we cover several new FDA approvals and a major prescription-to-OTC switch expanding therapeutic options.

• Veppanu (vepdegestrant): The first PROTAC (PROteolysis TArgeting Chimera) therapy to be approved for ESR1-mutated, ER+/HER2- advanced or metastatic breast cancer based on strong progression-free survival clinical data.
• Trimbow (beclomethasone dipropionate/formoterol fumarate/glycopyrrolate): A triple-combination inhalation aerosol approved for the long-term maintenance treatment of adult asthma.
• Xocova (ensitrelvir): The first oral antiviral tablet indicated for post-exposure prophylaxis (PEP) to prevent COVID-19 following exposure.
• Baxfendy (baxdrostat): A first-in-class oral aldosterone synthase inhibitor approved to treat uncontrolled hypertension in combination with other agents.
• Differin Epiduo Acne Gel (adapalene/benzoyl peroxide): A prescription combination acne treatment newly approved for over-the-counter (OTC) use.
• Zaynich (cefepime/zidebactam): An intravenous antibiotic approved for adults suffering from complicated urinary tract infections and pyelonephritis.
• Immgolis (golimumab-sldi): The first interchangeable biosimilar to Simponi approved for adult rheumatoid arthritis and ulcerative colitis.

Chapters:

• (00:20) - Intro

• X, Facebook, YouTube
• Sign up to our newsletters
• Download the app

In this April 2026 Monthly Update edition, we highlight several FDA approvals that introduce first-of-their-kind therapies and improve access to existing treatments.

• Foundayo (orforglipron): A first-of-its-kind small-molecule oral GLP-1 receptor agonist for chronic weight management without strict food or water requirements.
• Otarmeni (lunsotogene parvec-cwha): An innovative gene therapy for pediatric and adult patients with OTOF-related genetic hearing loss.
• Idvynso (doravirine and islatravir): A new once-daily, two-drug single-tablet regimen for adults with HIV-1 who are virologically suppressed.
• Langlara (insulin glargine-aldy): A interchangeable biosimilar to Lantus for the treatment of type 1 and type 2 diabetes.

Chapters:

• (00:21) - Intro

• X, Facebook, YouTube
• Sign up to our newsletters
• Download the app

In this March 2026 edition of Drugs.com Monthly Update Podcast, learn about the FDA's latest approvals, including Wegovy HD for obesity, Icotyde for plaque psoriasis, Sotyktu for psoriatic arthritis, and Awiqli for type 2 diabetes. 

Wegovy HD (semaglutide): A new high-dose option for adults managing obesity, showing significant weight loss in clinical trials.

Icotyde (icotrokinra): The first oral IL-23 blocker approved to treat moderate-to-severe plaque psoriasis, providing a new oral treatment choice.

Sotyktu (deucravacitinib): An oral TYK2 inhibitor now approved for treating active psoriatic arthritis, addressing inflammation with a convenient dosing regimen.

Awiqli (insulin isodec): The first once-weekly basal insulin for adults with type 2 diabetes.

Chapters:

• (00:21) - Intro

• X, Facebook, Youtube
• Sign up to our newsletters
• Download the app

In this February 2026 edition of Drugs.com Monthly Update Podcast, learn about new options in weight management, type 2 diabetes, and lung cancer. Discover Eli Lilly's Zepbound KwikPen for simplified dosing in obesity management, the upcoming launch of the oral Ozempic pill for diabetes by Novo Nordisk, IBSA Pharma’s oral film formulation of sildenafil for erectile dysfunction called Vybrique, and the monthly Rybrevant Faspro injection for advanced NSCLC.

• Zepbound KwikPen (tirzepatide): A new multidose Zepbound pen supplying 4 fixed weekly doses in one pen 
• Ozempic pill (semaglutide): Discover the upcoming once-daily oral option for adults with type 2 diabetes to manage blood sugar and cardiovascular risks.
• Rybrevant Faspro (amivantamab and hyaluronidase-lpuj): Explore the benefits of a simplified, monthly injectable regimen for EGFR-mutated NSCLC.
• Dupixent (dupilumab): The first approved therapy for allergic fungal rhinosinusitis, reducing the need for systemic steroids.
• Vybrique (sildenafil): A new oral film formulation of sildenafil for erectile dysfunction.
• Calquence + Venetoclax (acalabrutinib combination): This new all-oral regimen provides a targeted therapy for CLL, improving patient outcomes with a non-chemo approach.

Chapters:

• (00:00) - Intro

• X, Facebook, Youtube
• Signup to our newsletters
• Download the app

In our latest episode, we cover the latest approval of Darzalex Faspro for multiple myeloma, age-related near vision loss, and a rare genetic disorder affecting children. We also discuss an extension to the use of Nexplanon, a long-acting birth control, and a simpler transition for those moving from injected to inhaled insulin.

• Darzalex Faspro (daratumumab and hyaluronidase-fihj) a new approval for use in combination with standard treatments for adults with newly diagnosed multiple myeloma.
• Yuvezzi (carbachol and brimonidine tartrate), a novel combination eye drop for presbyopia.
• Zycubo (copper histidinate), the first treatment for Menkes disease in children.
• Nexplanon (etonogestrel), a birth control implant with an extension of use for up to five years.
• Afrezza (insulin human), an inhaled insulin, with updated dosing guidance.

Chapters

• (00:00) - Intro

• X, Facebook, Youtube
• Signup to our newsletters
• Download the app

This month, discover the Wegovy tablet, the first oral GLP-1 weight loss medication to be approved, Myqorzo's long-awaited treatment for obstructive hypertrophic cardiomyopathy, and several other exciting new FDA approvals. Explore these key stories and more in our December 2025 round-up.

• Wegovy (semaglutide) tablet, the first oral GLP-1 for weight loss, with significant efficacy in patient trials.
• Myqorzo (aficamten), a long-awaited and major addition to obstructive hypertrophic cardiomyopathy treatment that improves exercise capacity.
• Exdensur (depemokimab-ulaa), a new long-term, add-on treatment for severe eosinophilic asthma with twice-yearly injections.
• Jaypirca (pirtobrutinib), a non-covalent BTK inhibitor whose approval has been extended to include chronic lymphocytic leukemia and small lymphocytic lymphoma.
• Lerochol (lerodalcibep-liga), a third-generation, PCSK9 inhibitor for high cholesterol self-administered via a monthly injection.
• Breyanzi (lisocabtagene maraleucel), a CAR T cell therapy with extended approval to include relapsed or refractory marginal zone lymphoma.

Chapters

• (00:00) - Intro

• X, Facebook, Youtube
• Signup to our newsletters
• Download the app